Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis

Clinical Biochemistry

Volumn 41, Issue 14-15, 2008, Pages 1191-1198

  Neves, Adriana F ^a   Araújo, Thaise G ^a   Biase, Weruska K F S ^a   Meola, Juliana ^a   Alcântara, Tânia M ^a   Freitas, Danielo G ^a   Goulart, Luiz R ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

5 alpha reductase type 2; Androgen receptor; Benign prostatic hyperplasia; Human kallikrein 2; Prostate cancer; Prostate cancer antigen 3; Prostate specific antigen; Prostate specific membrane antigen; Reverse transcriptase polymerase chain reaction

Indexed keywords

ANDROGEN RECEPTOR; BIOCHEMICAL MARKER; KALLIKREIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; AR GENE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; KLK2 GENE; MALE; ONCOGENE; PCA3 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSMA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 55649093514     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.06.013     Document Type: Article

References (40)

1. Griffiths K., and Morton M.S. Aspects of the cell biology of prostate cancer. In: Kaisary A.V., Murphy G.P., and Denis L. (Eds). Textbook of prostate cancer: pathology, diagnosis and treatment (1999), Martin Dunitz Ltd, London 51-54
2. Makridakis N.M., Ross R.K., Pike M.C., et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 (1999) 975-978
3. Li Z., Habuchi T., Mitsumori K., et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 169 (2003) 2378-2381
4. Brinkmann A.O., Jenster G., Kuiper G.G., et al. The human androgen receptor: structure/function relationship in normal and pathological situations. J. Steroid. Biochem. Mol. Biol. 41 (1992) 361-368
5. Hong H., Kohli K., Trivedi A., Johnson D.L., and Stallcup M.R. GRP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4948-4952
6. Ikonen T., Palvimo J.J., and Jänne O. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J. Biol. Chem. 272 (1997) 29821-29828
7. Froesh B.A., Takayana S., and Reed J.C. BAG-1L protein enhancer androgen receptor function. J. Biol. Chem. 273 (1998) 11660-11666
8. Fujimoto N., Mizokami A., Harada S., and Matsumoto T. Different expression ofandrogen receptor coactivators in human prostate. Urology 58 (2001) 289-294
9. Sun Z., Pan J., and Balk S.P. Androgen receptor-associated protein complex binds upstream of the androgen responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucl. Acids. Res. 25 (1997) 3318-3325
10. Frenette G., Tremblay R.R., Lazure C., and Dube J.Y. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71 (1997) 897-899
11. Takayama T.K., Fujikawa K., and Davie E.W. Characterization of the precursor of prostate-specific antigen: activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272 (1997) 21582-21588
12. Ablin R.J., Soanes W.A., Bronson P., and Witebsky E. Precipitating antigens of the normal human prostate. J. Reprod. Fertil. 22 (1970) 573-574
13. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., and Heston W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 54 (1994) 1807-1811
14. Kawakami M., and Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57 (1997) 2321-2324
15. O'Keefe D.S., Su S.L., Bacich D.J., et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochem. Biophys. Acta 1443 (1998) 113-127
16. Laidler P., Dulińska J., Lekka M., and Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch. Biochem. Biophys. 435 (2005) 1-14
17. Llanes L., Ferruelo A., Páez A., Gómez J.M., Moreno A., and Berenguer A. The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells: an analysis in healthy men and women. BJU Int. 89 (2002) 882-885
18. Bussemakers M.J., Bokhoven A., van Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59 (1999) 5975-5979
19. Riegman P.H.J., Vlietstra R.J., Suurmeijer L., Cleutjens C.B.J.M., and Trapman J. Characterization of the human kallikrein locus. Genomics 14 (1991) 6-11
20. Santagati S., Garnier M., Carlo P., Violani E., Picotti G.B., and Maggi A. Quantification of low abundance mRNAs in glial cells using different polymerase chain reaction (PCR)-based methods. Brain Res. Brain Res. Protoc. 1 (1997) 217-223
21. Rose'Meyer R.B., Mellick A.S., Garnham B.G., Harrison G.J., Massa H.M., and Griffiths L.R. The measurement of adenosine and estrogen receptor expression in rat brains following ovariectomy using quantitative PCR analysis. Brain Res. Brain Res. Protoc. 11 (2003) 9-18
22. Pernas-Alonso R., Morelli F., di Porzio U., and Perrone-Capano C. Multiplex semi-quantitative reverse transcriptase-polymerase chain reaction of low abundance neuronal mRNAs. Brain Res. Brain Res. Protoc. 4 (1999) 395-406
23. Soderstrom T.G., Bjelfman C., Brekkan E., et al. Messenger ribonucleic acid levels of steroid 5-reductase 2 in human prostate predict the enzyme activity. J. Clin. Endocrinol. Metab. 86 (2001) 855-858
24. Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., and Schalken J.A. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62 (2002) 2695-2698
25. Latil A., Biecher I., Vidaud D., et al. Evaluation of androgen, estrogen (ER alpha and ER beta) and progesterone receptor expression human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61 (2001) 1919-1926
26. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61 (2001) 3550-3555
27. Habib F.K., Ross M., Bayne C.W., Bollina P., Grigor K., and Chapman K. The lossof 5a-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin. Cancer Res. 9 (2003) 1815-1819
28. Herrala A.M., Porvari K.S., Kyllönen A.P., and Vihko P.T. Comparison of humanprostate specific glandular kallikrein 2 and prostate-specific antigengene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 92 (2001) 2975-2984
29. Meola J., Goulart L.R., Oliveira J.D.D., et al. Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer. Gen. Mol. Biol. 29 (2006) 193-199
30. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44 (2003) 8-16
31. Oliveira J.D.D., Goulart L.R., Oliveira Jr. W.P., Meola J., and Neves A.F. DD3 gene expression in peripheral blood of patients with prostate cancer and with benign prostate hyperplasia as a molecular diagnostic. Eur. Urol. Suppl. 2 (2003) 102
32. Hessels D., Verhaegh G.W., Schalken J.A., and Witjes J.A. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev. Mol. Diagn. 4 (2004) 513-526
33. Brinkmann A.O., Jenster G., Ris-Stalpers C., et al. Androgen receptor mutations. J. Steroid. Biochem. Mol. Biol. 53 (1995) 443-448
34. Wallen M.J., Linja M., Kaartinen K., Schleuzker J., and Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. Am. J. Pathol. 189 (1999) 559-563
35. Culig Z., Hobisch A., Hittmair A., et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35 (1998) 63-70
36. Culig Z., Hobisch A., Bartsch G., and Klocker H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol. Res. 28 (2000) 211-219
37. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53 (1999) 939-944
38. Wright G.L., Haley C., Beckett M.L., and Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1 (1995) 18-28
39. Sweat S.D., Pacelli A., Murphy G.P., and Bostwick D.G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52 (1998) 637-640
40. Silver D.A., Pellicer I., Fair W.R., Heston W.D.W., and Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3 (1997) 81-85